Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients

Tuba Bukhari; Mariya Markovina; Abrahim Abduelmula; Brian D Rankin; Ronald Vender; Jensen Yeung; Alim R Devani; Vimal H Prajapati

Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients

Skin Therapy Lett. 2024 Jan;29(1):1-4.

Authors

Tuba Bukhari¹, Mariya Markovina¹, Abrahim Abduelmula², Brian D Rankin³, Ronald Vender^{4

5}, Jensen Yeung^{6

7

8

9}, Alim R Devani^{1

9

10}, Vimal H Prajapati^{1

3

9

10

11

12}

Affiliations

¹ Dermatology Research Institute, Calgary, AB, Canada.
² Faculty of Medicine, University of Western Ontario, London, ON, Canada.
³ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
⁴ Department of Dermatology, McMaster University, Hamilton, ON, Canada.
⁵ Dermatrials Research Inc. & Venderm Consulting, Hamilton, ON, Canada.
⁶ Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
⁷ Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
⁸ Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
⁹ Probity Medical Research, Waterloo, ON, Canada.
¹⁰ Skin Health & Wellness Centre, Calgary, AB, Canada.
¹¹ Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
¹² Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.

PMID: 38271532

Abstract

Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials.

Keywords: biologics; clinical trial; generalized pustular psoriasis; interleukin-36; spesolimab.

Publication types

Review

MeSH terms

Acute Disease
Adult
Antibodies, Monoclonal, Humanized / therapeutic use
Chronic Disease
Exanthema*
Humans
Interleukin Inhibitors
Interleukins / genetics
Interleukins / therapeutic use
Psoriasis* / drug therapy
Skin Diseases, Vesiculobullous*

Substances

spesolimab
Interleukin Inhibitors
Interleukins
Antibodies, Monoclonal, Humanized
IL36RN protein, human